1-(3-{[cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-2,3-dimethyl-1H-imidazol-3-ium iodide | 1051920-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-{[cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-2,3-dimethyl-1H-imidazol-3-ium iodide
• 英文别名: 3-(2,3-Dimethylimidazol-3-ium-1-yl)propyl 2-cycloheptyl-2-hydroxy-2-phenylacetate;iodide
• CAS: 1051920-38-7
• 化学式: C₂₃H₃₃N₂O₃*I
• 分子量: 512.431
• InChiKey: BKVLZISRBPTGOX-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.42
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  55.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Kumar Naresh

  公开号：US20100168197A1

  公开（公告）日：2010-07-01

  This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

  这项发明通常涉及肌肉型受体拮抗剂，这些拮抗剂可用于治疗通过肌肉型受体介导的呼吸系统、泌尿系统和消化系统的各种疾病，此外，该发明还涉及所述化合物的制备过程、含有所述化合物的制药组合物以及治疗通过肌肉型受体介导的疾病的方法。
• [EN] MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES
  申请人：RANBAXY LAB LTD

  公开号：WO2008104942A2

  公开（公告）日：2008-09-04

  [EN] This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
  [FR] L'invention porte sur des antagonistes des récepteurs muscariniques, notamment utiles pour traiter différentes maladies des systèmes respiratoire, urinaire et gastro-intestinal, médiées par les récepteurs muscariniques. L'invention porte également: sur le procédé de préparation desdits composés; sur des préparations pharmaceutiques les comprenant, et sur des méthodes de traitement de maladies médiées par les récepteurs muscariniques.